Eli Lilly Enters Psychedelic Mental Health Space with $3.8 Billion AtaiBeckley Acquisition
Eli Lilly secures BPL-003 and other novel psychedelic-inspired treatments designed to provide rapid, long-lasting relief for treatment-resistant depression.
/ 1648 items
#XY↓
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Novo’s Wegovy Pill Crushes Lilly’s Foundayo in Early Weight-Loss Battle
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.
Veradermics Surges on Analyst Backing and Promising Oral Hair Loss Data in Women
90% of women reported improved hair coverage with no major safety issues.
Johnson & Johnson Q2 2026 Earnings: Beat and Raise, But Shares Slip on MedTech Miss
The company raised full-year guidance and remains on track for its first $100 billion revenue year.
Elevance Health Reports Strong Q2 Beat but Shares Slide on Rising Medical Costs and Lower Margins
Despite beating Q2 estimates and lifting 2026 guidance, Elevance Health saw margins compress sharply. Core operating margin fell to 3.5% on higher medical costs.